Stock Track | PTC Therapeutics Soars 5.57% on Strong Q1 Earnings Beat and Raised Guidance

Stock Track

May 08

PTC Therapeutics' stock surged 5.57% during the trading session, reflecting strong investor optimism following the company's latest financial results.

The biopharmaceutical company reported first-quarter 2026 revenue of $273 million, significantly beating analyst consensus estimates of approximately $225 million. Additionally, the company posted an adjusted loss per share of $0.03, which was a substantial improvement over the expected loss of $0.48 per share.

Investor sentiment was further bolstered by the company's decision to raise its full-year 2026 guidance. PTC Therapeutics now expects total revenue to be in the range of $1.08 billion to $1.18 billion, up from previous estimates and above the consensus forecast. The strong quarterly performance was primarily driven by a 47% year-over-year increase in product revenue, fueled by the successful launch of its drug Sephience.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1111426553"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1111426553\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1111426553?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 14:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111426553","market":"nz","top_or_hot":-1,"title":"Stock Track | PTC Therapeutics Soars 5.57% on Strong Q1 Earnings Beat and Raised Guidance","media":"Stock Track","content":"<p>PTC Therapeutics' stock surged 5.57% during the trading session, reflecting strong investor optimism following the company's latest financial results.</p><p>The biopharmaceutical company reported first-quarter 2026 revenue of $273 million, significantly beating analyst consensus estimates of approximately $225 million. Additionally, the company posted an adjusted loss per share of $0.03, which was a substantial improvement over the expected loss of $0.48 per share.</p><p>Investor sentiment was further bolstered by the company's decision to raise its full-year 2026 guidance. PTC Therapeutics now expects total revenue to be in the range of $1.08 billion to $1.18 billion, up from previous estimates and above the consensus forecast. The strong quarterly performance was primarily driven by a 47% year-over-year increase in product revenue, fueled by the successful launch of its drug Sephience.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | PTC Therapeutics Soars 5.57% on Strong Q1 Earnings Beat and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | PTC Therapeutics Soars 5.57% on Strong Q1 Earnings Beat and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-08 14:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>PTC Therapeutics' stock surged 5.57% during the trading session, reflecting strong investor optimism following the company's latest financial results.</p><p>The biopharmaceutical company reported first-quarter 2026 revenue of $273 million, significantly beating analyst consensus estimates of approximately $225 million. Additionally, the company posted an adjusted loss per share of $0.03, which was a substantial improvement over the expected loss of $0.48 per share.</p><p>Investor sentiment was further bolstered by the company's decision to raise its full-year 2026 guidance. PTC Therapeutics now expects total revenue to be in the range of $1.08 billion to $1.18 billion, up from previous estimates and above the consensus forecast. The strong quarterly performance was primarily driven by a 47% year-over-year increase in product revenue, fueled by the successful launch of its drug Sephience.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PTCT","symbol_name":"PTC Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1111426553","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111426553","pubTimestamp":1778220789,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"PTC Therapeutics' stock surged 5.57% during the trading session, reflecting strong investor optimism following the company's latest financial results.The biopharmaceutical company reported...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PTCT":"PTC Therapeutics Inc."},"translate_title":"股票追踪|PTC Therapeutics飙升5.57%，第一季度盈利强劲，指引上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTCT":1},"content_text":"PTC Therapeutics' stock surged 5.57% during the trading session, reflecting strong investor optimism following the company's latest financial results.The biopharmaceutical company reported first-quarter 2026 revenue of $273 million, significantly beating analyst consensus estimates of approximately $225 million. Additionally, the company posted an adjusted loss per share of $0.03, which was a substantial improvement over the expected loss of $0.48 per share.Investor sentiment was further bolstered by the company's decision to raise its full-year 2026 guidance. PTC Therapeutics now expects total revenue to be in the range of $1.08 billion to $1.18 billion, up from previous estimates and above the consensus forecast. The strong quarterly performance was primarily driven by a 47% year-over-year increase in product revenue, fueled by the successful launch of its drug Sephience.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}